Targeting HSV gB Protein with Nanobodies: A Breakthrough for Herpesvirus Treatment Challenges
Herpes Simplex Virus comprises HSV‑1 and HSV‑2, causing oral and genital herpes respectively. Both can lead to severe complications. Current drugs such as acyclovir only inhibit replication but not latency or recurrence. Conformational changes in gB also drive increasing drug resistance.
Read More...